Prabhala P, Bunge K, Rahman MM, Ge Q, Clark AR, Ammit AJ. Temporal regulation of cytokine mRNA expression by tristetraprolin: dynamic control by p38 MAPK and MKP-1. Am J Physiol Lung Cell Mol Physiol 308: L973-L980, 2015. First published February 27, 2015 doi:10.1152/ajplung.00219.2014.-Cytokines drive many inflammatory diseases, including asthma. Understanding the molecular mechanisms responsible for cytokine secretion will allow us to develop novel strategies to repress inflammation in the future. Harnessing the power of endogenous anti-inflammatory proteins is one such strategy. In this study, we investigate the p38 MAPKmediated regulatory interaction of two anti-inflammatory proteins, mitogen-activated protein kinase phosphatase 1 (MKP-1) and tristetraprolin (TTP), in the context of asthmatic inflammation. Using primary cultures of airway smooth muscle cells in vitro, we explored the temporal regulation of IL-6 cytokine mRNA expression upon stimulation with TNF-␣. Intriguingly, the temporal profile of mRNA expression was biphasic. This was not due to COX-2-derived prostanoid upregulation, increased expression of NLRP3 inflammasome components, or upregulation of the cognate receptor for TNF-␣-TNFR1. Rather, the biphasic nature of TNF-␣-induced IL-6 mRNA expression was regulated temporally by the RNA-destabilizing molecule, TTP. Importantly, TTP function is controlled by p38 MAPK, and our study reveals that its expression in airway smooth muscle cells is p38 MAPK-dependent and its anti-inflammatory activity is also controlled by p38 MAPK-mediated phosphorylation. MKP-1 is a MAPK deactivator; thus, by controlling p38 MAPK phosphorylation status in a temporally distinct manner, MKP-1 ensures that TTP is expressed and made functional at precisely the correct time to repress cytokine expression. Together, p38 MAPK, MKP-1, and TTP may form a regulatory network that exerts significant control on cytokine secretion in proasthmatic inflammation through precise temporal signaling. p38 MAPK; tristetraprolin; MKP-1; inflammation; IL-6 MANY CHRONIC INFLAMMATORY diseases are a common consequence of overactive inflammatory signaling pathways. Hence, using these pathways as potential drug targets represents a way to re-establish control and attenuate the severity of such chronic inflammatory diseases. Asthma is a chronic inflammatory disease, which is characterized by reversible airway obstruction, structural remodeling, and airway hyperresponsiveness. A plethora of proinflammatory cytokines have been implicated in the pathophysiology of asthma. The common therapies for asthma include glucocorticoids and  2 -agonists; however, there is still a proportion of the population for which this treatment is ineffective. Hence, a need has arisen to find alternative anti-inflammatory strategies, such as using smallmolecule inhibitors of inflammatory cascades or using agents that could increase activity of anti-inflammatory proteins. To achieve this goal, a greater understanding of the regulatory networks that control cytokines are u...